Slingshot members are tracking this event:

Arrowhead Pharma (ARWR) to Initiate Phase IIA Study in 2016 Evaluating ARC-AAT in Liver Disease Associated With a Genetic Disorder Causing Alpha-1 Antitrypsin Deficiency (AATD)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 06, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase Iia, Arc-aat, Liver Disease, Alpha-1 Antitrypsin Deficiency